|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng M: Classification and Pathology of
Lung Cancer. Surg Oncol Clin N Am. 25:447–468. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosell R and Karachaliou N: Lung cancer:
Maintenance therapy and precision medicine in NSCLC. Nat Rev Clin
Oncol. 10:549–550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spellmon N, Holcomb J, Trescott L,
Sirinupong N and Yang Z: Structure and function of SET and MYND
domain-containing proteins. Int J Mol Sci. 16:1406–1428. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamamoto R, Furukawa Y, Morita M, Iimura
Y, Silva FP, Li M, Yagyu R and Nakamura Y: SMYD3 encodes a histone
methyl-transferase involved in the proliferation of cancer cells.
Nat Cell Biol. 6:731–740. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cock-Rada AM, Medjkane S, Janski N, Yousfi
N, Perichon M, Chaussepied M, Chluba J, Langsley G and Weitzman JB:
SMYD3 promotes cancer invasion by epigenetic upregulation of the
metalloproteinase MMP-9. Cancer Res. 72:810–820. 2012. View Article : Google Scholar :
|
|
7
|
Hamamoto R, Silva FP, Tsuge M, Nishidate
T, Katagiri T, Nakamura Y and Furukawa Y: Enhanced SMYD3 expression
is essential for the growth of breast cancer cells. Cancer Sci.
97:113–118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sarris ME, Moulos P, Haroniti A,
Giakountis A and Talianidis I: Smyd3 Is a transcriptional
potentiator of multiple cancer-promoting genes and required for
liver and colon cancer development. Cancer Cell. 29:354–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu Y, Zhu MX, Zhang XD, Xu XE, Wu ZY,
Liao LD, Li LY, Xie YM, Wu JY, Zou HY, et al: SMYD3 stimulates EZR
and LOXL2 transcription to enhance proliferation, migration, and
invasion in esophageal squamous cell carcinoma. Hum Pathol.
52:153–163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Deng J, Luo X, Pan Y, Zhang L,
Zhang R and Liang H: Overexpression of SMYD3 was associated with
increased STAT3 activation in gastric cancer. Med Oncol.
32:4042015. View Article : Google Scholar
|
|
11
|
Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y
and Fan Y: Upregulated SMYD3 promotes bladder cancer progression by
targeting BCLAF1 and activating autophagy. Tumour Biol.
37:7371–7381. 2016. View Article : Google Scholar
|
|
12
|
Liu C, Wang C, Wang K, Liu L, Shen Q, Yan
K, Sun X, Chen J, Liu J, Ren H, et al: SMYD3 as an oncogenic driver
in prostate cancer by stimulation of androgen receptor
transcription. J Natl Cancer Inst. 105:1719–1728. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dai B, Wan W, Zhang P, Zhang Y, Pan C,
Meng G, Xiao X, Wu Z, Jia W, Zhang J, et al: SET and MYND
domain-containing protein 3 is overexpressed in human glioma and
contributes to tumorigenicity. Oncol Rep. 34:2722–2730. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang SZ, Luo XG, Shen J, Zou JN, Lu YH and
Xi T: Knockdown of SMYD3 by RNA interference inhibits cervical
carcinoma cell growth and invasion in vitro. BMB Rep. 41:294–299.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsuge M, Hamamoto R, Silva FP, Ohnishi Y,
Chayama K, Kamatani N, Furukawa Y and Nakamura Y: A variable number
of tandem repeats polymorphism in an E2F-1 binding element in the
5′ flanking region of SMYD3 is a risk factor for human cancers. Nat
Genet. 37:1104–1107. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barlési F, Giaccone G, Gallegos-Ruiz MI,
Span SW, Lefesvre P, Kruyt FA and Rodriguez JA: Genotype analysis
of the VNTR polymorphism in the SMYD3 histone methyltransferase
gene: Lack of correlation with the level of histone H3 methylation
in NSCLC tissues or with the risk of NSCLC. Int J Cancer.
122:1441–1442. 2008. View Article : Google Scholar
|
|
17
|
Fedor HL and De Marzo AM: Practical
methods for tissue microarray construction. Methods Mol Med.
103:89–101. 2005.
|
|
18
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 136:260–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
You W, Chen B, Liu X, Xue S, Qin H and
Jiang H: Farnesoid X receptor, a novel proto-oncogene in non-small
cell lung cancer, promotes tumor growth via directly
transactivating CCND1. Sci Rep. 7:5912017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong SW, Zhang H, Wang BL, Sun P, Wang YG
and Zhang P: Effect of the downregulation of SMYD3 expression by
RNAi on RIZ1 expression and proliferation of esophageal squamous
cell carcinoma. Oncol Rep. 32:1064–1070. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kunizaki M, Hamamoto R, Silva FP,
Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y and Furukawa Y: The
lysine 831 of vascular endothelial growth factor receptor 1 is a
novel target of methylation by SMYD3. Cancer Res. 67:10759–10765.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Indran IR, Tufo G, Pervaiz S and Brenner
C: Recent advances in apoptosis, mitochondria and drug resistance
in cancer cells. Biochim Biophys Acta. 1807:735–745. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rossi A and Di Maio M: Platinum-based
chemotherapy in advanced non-small-cell lung cancer: Optimal number
of treatment cycles. Expert Rev Anticancer Ther. 16:653–660. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giakountis A, Moulos P, Sarris ME, Hatzis
P and Talianidis I: Smyd3-associated regulatory pathways in cancer.
Semin Cancer Biol. 42:70–80. 2017. View Article : Google Scholar
|
|
25
|
Mazur PK, Reynoird N, Khatri P, Jansen PW,
Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak
D, et al: SMYD3 links lysine methylation of MAP3K2 to Ras-driven
cancer. Nature. 510:283–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cory S and Adams JM: The Bcl2 family:
Regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ren TN, Wang JS, He YM, Xu CL, Wang SZ and
Xi T: Effects of SMYD3 over-expression on cell cycle acceleration
and cell proliferation in MDA-MB-231 human breast cancer cells. Med
Oncol. 28(Suppl 1): S91–S98. 2011. View Article : Google Scholar
|
|
28
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and
Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2
phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Perego P, Giarola M, Righetti SC, Supino
R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and
Zunino F: Association between cisplatin resistance and mutation of
p53 gene and reduced bax expression in ovarian carcinoma cell
systems. Cancer Res. 56:556–562. 1996.PubMed/NCBI
|
|
30
|
Zhou Z, Jiang H, Tu K, Yu W, Zhang J, Hu
Z, Zhang H, Hao D, Huang P, Wang J, et al: ANKHD1 is required for
SMYD3 to promote tumor metastasis in hepatocellular carcinoma. J
Exp Clin Cancer Res. 38:182019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo XG, Zhang CL, Zhao WW, Liu ZP, Liu L,
Mu A, Guo S, Wang N, Zhou H and Zhang TC: Histone methyltransferase
SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and
migration of MCF-7 breast cancer cells. Cancer Lett. 344:129–137.
2014. View Article : Google Scholar
|
|
32
|
Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH
and Xi T: Knockdown of SMYD3 by RNA interference down-regulates
c-Met expression and inhibits cells migration and invasion induced
by HGF. Cancer Lett. 280:78–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gonzalez-Avila G, Sommer B, Mendoza-Posada
DA, Ramos C, Garcia-Hernandez AA and Falfan-Valencia R: Matrix
metal-loproteinases participation in the metastatic process and
their diagnostic and therapeutic applications in cancer. Crit Rev
Oncol Hematol. 137:57–83. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sims RJ III and Reinberg D: From chromatin
to cancer: A new histone lysine methyltransferase enters the mix.
Nat Cell Biol. 6:685–687. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang L and Xu AM: SET and MYND domain
containing protein 3 in cancer. Am J Transl Res. 9:1–14.
2017.PubMed/NCBI
|
